Claims for Patent: 8,084,475

Summary for Patent: 8,084,475

Title:	Pirfenidone therapy and inducers of cytochrome P450
Abstract:	The present invention relates to methods involving avoiding adverse drug interactions with pirfenidone and CYP inducers, such as smoking.
Inventor(s):	Bradford; Williamson Ziegler (Ross, CA), Szwarcberg; Javier (San Francisco, CA)
Assignee:	Intermune, Inc. (Brisbane, CA)
Application Number:	12/684,543
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,084,475
Patent Claims:	1. A method of administering pirfenidone therapy to a patient in need thereof, wherein said patient is also in need of a strong inducer of CYP1A2 other than cigarette smoke, comprising (a) administering to the patient a therapeutically effective amount of pirfenidone and (b) avoiding concomitant administration of said strong inducer of CYP1A2. 2. The method of claim 1, wherein the patient has idiopathic pulmonary fibrosis (IPF). 3. The method of claim 1, wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day. 4. A method of administering pirfenidone therapy to a patient in need thereof, wherein said patient is receiving a strong inducer of CYP1A2 other than cigarette smoke, comprising (a) first discontinuing administration of the strong inducer of CYP1A2, and then (b) administering to the patient a therapeutically effective amount of pirfenidone. 5. The method of claim 4, wherein the patient discontinues administration of said strong inducer of CYP1A2 concurrent to administration of pirfenidone. 6. The method of claim 4, wherein the patient has idiopathic pulmonary fibrosis (IPF). 7. The method of claim 4, wherein the therapeutically effective amount of pirfenidone is a daily dosage of 2400 mg or 2403 mg per day. 8. A method of increasing the effectiveness of pirfenidone in the treatment of idiopathic pulmonary fibrosis (IPF) in a patient that is receiving a CYP1A2 inducer, comprising discontinuing the CYP1A2 inducer within 4 weeks prior to pirfenidone administration to decrease the levels of CYP1A2 induction, and then administering pirfenidone. 9. The method of claim 8, wherein the amount of pirfenidone is administered at a daily dosage of 2400 mg or 2403 mg per day. 10. The method of claim 8, wherein the patient is a current smoker and smoking is discontinued within 4 weeks prior to pirfenidone administration. 11. The method of claim 10, wherein the pirfenidone is administered at a daily dosage of 2400 mg or 2403 mg per day.